Journal
CURRENT DERMATOLOGY REPORTS
Volume 3, Issue 1, Pages 46-53Publisher
SPRINGER
DOI: 10.1007/s13671-014-0068-z
Keywords
Merkel cell carcinoma; Merkel cell polyomavirus; Immunosuppression; Sentinel lymph node biopsy; Immune therapy; Chemotherapy; Radiation therapy; Signaling pathway
Categories
Ask authors/readers for more resources
Merkel cell carcinoma (MCC) is an aggressive neuroendocrine tumor of the skin with a rising incidence. MCC has metastatic potential regardless the size of the primary tumor and a 5-year disease associated mortality rate is 46 %. Surgery and radiation are the mainstays of management for primary MCC. There is no evidence-based effective chemotherapy for recurrent or metastatic diseases to date. In-depth mechanistic studies in MCC have uncovered important cellular events and the association with a polyomavirus, which has provided direct evidence for molecular targeted and immunotherapy. Further perspective studies and clinical trials are warranted to provide reliable evidence of possible pitfalls and effectiveness of molecular targeted immunotherapy alone or in combination with chemotherapy in MCC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available